<div id="readability-page-1"><p>DAVENPORT &amp; Co LLC lifted its holdings in shares of  DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 84,967 shares of the medical device company's stock after buying an additional 15,024 shares during the period. DAVENPORT &amp; Co LLC's holdings in DexCom were worth $5,717,000 at the end of the most recent quarter.</p><ul><li>From Dividends to Growth: Why These 3 Stocks Stand Out in 2025</li></ul><p>Several other institutional investors have also recently added to or reduced their stakes in DXCM. SWS Partners acquired a new stake in shares of  DexCom in the 2nd quarter worth $1,661,000.  Baader Bank Aktiengesellschaft purchased a new stake in  DexCom in the 2nd quarter valued at approximately $393,000.  Jennison Associates LLC increased its position in  DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company's stock worth $1,005,367,000 after purchasing an additional 994,300 shares during the period.  Mn Services Vermogensbeheer B.V. increased its position in  DexCom by 4.9% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company's stock worth $12,797,000 after purchasing an additional 6,800 shares during the period.  Finally, Assenagon Asset Management S.A. boosted its stake in shares of  DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company's stock valued at $105,469,000 after buying an additional 557,576 shares in the last quarter. Institutional investors and hedge funds own  97.75% of the company's stock. </p><h2>DexCom Trading Up 0.4%</h2><p>Shares of DXCM opened at $67.15 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The firm has a 50 day simple moving average of $64.05 and a 200-day simple moving average of $73.31. The stock has a market cap of $26.19 billion, a price-to-earnings ratio of 37.30, a price-to-earnings-growth ratio of 1.45 and a beta of 1.51. </p><ul><li>Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside</li></ul><p>DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts' consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion during the quarter, compared to analysts' expectations of $1.18 billion. During the same period in the previous year, the firm posted $0.45 earnings per share. The business's revenue for the quarter was up 21.6% compared to the same quarter last year.  Equities analysts forecast that  DexCom, Inc. will post 2.03 EPS for the current fiscal year. </p><h2>Insider Activity at DexCom</h2><p>In other news, COO Jacob Steven Leach bought 18,200 shares of the firm's stock in a transaction that occurred on Monday, November 10th. The shares were purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares in the company, valued at $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares of the company's stock, valued at $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is owned by insiders. </p><h2>Analysts Set New Price Targets</h2><ul><li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li></ul><p>DXCM has been the subject of several research analyst reports. Oppenheimer cut DexCom from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Monday, September 8th. Stifel Nicolaus began coverage on shares of DexCom in a report on Tuesday, October 21st. They issued a &#34;buy&#34; rating and a $85.00 price target for the company. Cowen  reiterated a &#34;buy&#34; rating on shares of DexCom in a research note on Friday, October 24th. Wall Street Zen cut shares of DexCom from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Sunday, November 16th. Finally, Morgan Stanley raised DexCom from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and boosted their price target for the stock from $63.00 to $75.00 in a research note on Tuesday, December 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned  a Buy rating, five have issued  a Hold rating and one  has given a Sell rating to the stock. According to MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $86.61.</p><p><b>Get Our Latest Stock Analysis on DXCM</b></p><h2>DexCom Company Profile</h2> (Free Report)<p>DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.  </p><p>Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.</p><h2>See Also</h2><ul><li>Five stocks we like better than DexCom</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li><li>33,000% boom from weird new “AI Fuel?”</li></ul><p><strong>Want to see what other hedge funds are holding DXCM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in DexCom Right Now?</h2><p>Before you consider DexCom, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DXCM

<p>DAVENPORT & Co LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 21.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC.</p>

DAVENPORT & Co LLC Increases Position in DexCom, Inc. $DXCM